Edwards Lifesciences, Stifel
Edwards Lifesciences Corp. engages in the ... Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart ...
Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business ...
Edwards Lifesciences stock lost almost a third of its value Thursday, undercutting the lower boundary of its base, after the medtech giant slashed its outlook for some heart-valve replacements ...
Favorable hospitalization trend, strong adoption of transcatheter heart valves and improved procedural volume are expected to have aided EW in the fourth quarter.
In the latest quarter, 11 analysts provided ratings for Edwards Lifesciences EW, showcasing a mix of bullish and bearish ...
“The two had a conversation.” Starr convinced Edwards they needed a successful artificial heart valve first and they agreed to embark on an ambitious project, each offering expertise in their ...
GlobalData analysts anticipate FDA approval for the JenaValve Trilogy TAVR device designed to treat aortic regurgitation (AR) ...
So much in life is determined by being in the right place at the right time, and by being prepared and bold enough to seize opportunities as they present themselves. I was prepared in large part ...
The global heart valve frame market is poised for significant growth over the coming years, driven by factors such as increasing prevalence of cardiovascular ...
Edwards Lifesciences Corp ... Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care. It operates through the ...
Geneos Wealth Management Inc. decreased its stake in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 2.3% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results